ArticleLife (Basel, Switzerland)2026
The Role of HLA-B Typing in Behçet's Disease and Spondyloarthritis: Genetic and Clinical Insights.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HLA-B*51 Beyond Behcet's Disease: Topography of Symptoms, Associated Diagnoses, and Characterization of Chronic Inflammatory Arthritis Phenotypes.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBehçet's disease (BD) is a systemic inflammatory disorder marked by recurrent mucocutaneous and ocular manifestations, predominantly affecting populations along the historic Silk Road. Genetic susceptibility, especially involving HLA-B*51, is well established. Spondyloarthritis (SpA) shares immunogenetic and clinical overlaps with BD, notably through associations with HLA class I alleles, particularly HLA-B*27. However, extended HLA-B allele profiling in these conditions remains limited. This study aimed to investigate the extended distribution of HLA-B alleles in patients presenting with clinical features suggestive of BD or SpA and to compare their clinical and laboratory profiles.
methodsIn a prospective observational study at a Bulgarian rheumatology center, 120 patients with suspected BD or SpA were enrolled between January 2023 and June 2025. Diagnoses were confirmed using International Criteria for Behçet's Disease (ICBD) and ASAS criteria for SpA. Comprehensive clinical evaluations, laboratory assessments including HLA-B typing by Sanger sequencing, and inflammatory markers were collected and analyzed.
resultsOf the cohort, 15 patients (12.5%) were diagnosed with BD and 30 (25%) with SpA. HLA-B*51 was predominantly associated with BD, while HLA-B*27 and its heterozygous combinations were prevalent in SpA patients. Suspected BD patients exhibited significantly higher levels of inflammatory markers (CRP, ESR) and characteristic clinical features such as oral/genital ulcers and uveitis compared to non-BD patients. Suspected SpA patients showed longer disease duration, increased NSAID use and higher prevalence of enthesitis, psoriasis and peripheral arthritis compared to non-SpA patients.
conclusionsThis study confirms the strong associations of HLA-B*51 with Behçet's disease and HLA-B*27 with spondyloarthritis while revealing additional heterozygous and less common alleles that suggest a broader genetic influence. These findings highlight the genetic diversity and clinical heterogeneity of BD and SpA, supporting the use of extended HLA typing to improve the diagnosis and understanding of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.